Future Medicine

About Future Medicine

Future Medicine Co., Ltd. is a South Korean biopharmaceutical firm established in 2015, operating as a publicly traded entity on the KONEX market. The company's strategic leadership is dually managed by co-CEOs, with founder Dr. Jeong Nak-shin overseeing research and development, while Jeong Wan-seok directs the business and management aspects. Dr. Jeong is a distinguished academic, holding a Ph.D. in Medicinal Chemistry from the University of Georgia and serving as a professor at Seoul National University's College of Pharmacy, bringing extensive expertise in drug development. Jeong Wan-seok complements this with a background that includes an MBA from Tsinghua University and executive experience at companies such as C&Group and Sunny Electronics.

The company's operational core is its proprietary 'FOCUS™' platform, a technology designed to expedite the discovery of new drug candidates. This platform leverages a library of nucleoside derivatives to identify compounds with high specificity for various cellular targets. By integrating artificial intelligence, Future Medicine aims to significantly shorten the typically lengthy drug development cycle, reducing the timeline from target identification to candidate selection to as little as six months. The business model is centered on advancing these candidates through preclinical and early-phase clinical trials before seeking out-licensing agreements and technology transfers with larger pharmaceutical partners, thereby generating revenue through these strategic collaborations.

Future Medicine's development pipeline is focused on addressing diseases with significant unmet medical needs. Its leading candidate, FM101, is being investigated for multiple indications. It is currently in Phase 2 clinical trials for the treatment of Non-Alcoholic Steatohepatitis (NASH) and as a potential world-first oral treatment for glaucoma. For NASH, the compound works by modulating the A3 adenosine receptor to control liver inflammation and fibrosis. The glaucoma treatment aims to both lower intraocular pressure and protect the optic nerve. Other pipeline programs target conditions such as diabetic nephropathy, primary biliary cholangitis, and various forms of cancer, including refractory pancreatic cancer and solid tumors.